ArticleNPJ vaccines2025
A replicating RNA vaccine protects against severe fever with thrombocytopenia syndrome virus infection in mice.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pre-existing immunity to heartland virus protects rhesus macaques from challenge with severe fever with thrombocytopenia syndrome virus.Emerging microbes & infections · 2026Article
- TRIM21 Neutralizes Hazara Virus Using a Dual Mechanism of Nucleoprotein Caging and Ubiquitination.Viruses · 2026Article
- SFTSV: a priority pathogen in need of a cure-reviewing the therapeutic.Archives of microbiology · 2026Review
- Multidimensional mechanisms of SFTSV-host interactions: viral protein functions, mFrontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No approved vaccines are currently available for Severe fever with thrombocytopenia syndrome virus (SFTSV). SFTSV is a tick-borne RNA virus with a case fatality rate ranging from 5 to 30% and is considered by the WHO to be a priority pathogen. Here, we evaluated a replicating RNA (repRNA) vaccine for protection against lethal SFTSV challenge in mice. We found that a repRNA-expressed SFTSV nucleoprotein (repNP) or glycoprotein precursor (repGPC) could confer protection, identifying both as protective antigens for SFTSV vaccine development. Furthermore, protection by our repNP vaccine required the intracellular Fc receptor TRIM21 for optimal protection, expanding the role of anti-NP antibodies and TRIM21 in control of bunyaviruses. Our data support continued development of this vaccine for SFTSV.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.